Sienna Biopharmaceuticals Ups Series A To $46M

Westlake Village-based Sienna Biopharmaceuticals has had a second close on its Series A funding, bringing the total raised in the round to $46M, the company said on Tuesday. The funding was led by ARCH Venture Partners and Partner Fund Management, and also included Two River, Altitude Life Science Ventures, Venvest Capital, and angels. Sienna Pharmaceuticals said the new funding will go towards its pharmaceutical research efforts and business development. Sienna is initially targeting the medical dermatology and aesthetic market, with a product used for acne and permanent hair removal. Sienna is led by Frederick C. Beddingfield III. The company's executive team was previously at Kythera. More information »